Trimarchi Thomas's Form 4 filing
BridgeBio Pharma, Inc. (BBIO) · filed Aug 19, 2025
- Accession no.
- 0000950170-25-110274
- Filed
- Aug 19, 2025
- Trade date
- Aug 16-18, 2025
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $871.7K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Trimarchi ThomasCIK 0002030813 | Officer (President and CFO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 16, 2025 | Common Stock | FTax withholdingDisposed | −21,317 | $51.32 | −$1,093,988.44 | 480,671 | Direct | |
| Aug 18, 2025 | Common Stock | SSaleDisposed | −15,380 | $50.14 | −$771,153.2 | 465,291 | Direct | |
| Aug 18, 2025 | Common Stock | SSaleDisposed | −1,973 | $50.94 | −$100,504.62 | 463,318 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.